STOCK TITAN

Pacific Biosciences of California (PACB) Stock Price, News & Analysis

PACB NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
88 252 sessions, November 13, 2025 to November 13, 2026
Largest daily move
+29.5% close of September 30, 2026
1-year change
+20.2% closing prices, November 13, 2025 to November 13, 2026
1-month change
-4.4% closing prices, October 13, 2026 to November 13, 2026

Company Description

Pacific Biosciences of California, Inc. (PacBio) (NASDAQ: PACB) is a life science technology company that designs, develops, and manufactures advanced sequencing solutions for genetic analysis. According to the company’s own descriptions in multiple press releases, PacBio focuses on high-quality, highly accurate sequencing technologies that help scientists and clinical researchers resolve genetically complex problems across a broad range of research areas.

PacBio operates in the analytical laboratory instrument manufacturing industry within the manufacturing sector. As described in its business overview and investor communications, the company develops, manufactures, and markets an integrated platform for genetic analysis and sequencing. Its solutions are used in applications such as human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging genomics research areas.

Core technologies and sequencing approach

PacBio emphasizes HiFi long-read sequencing as a central technology across its product and application portfolio. In multiple news releases, the company describes HiFi sequencing as a high-accuracy long-read approach that can detect complex genomic variants, resolve challenging regions of the genome, and provide comprehensive variant detection in a single whole-genome assay. PacBio notes that its products and technologies, which include HiFi long-read sequencing, are provided for research use only and are not for use in diagnostic procedures.

The company also references its Revio and Vega systems in financial updates, highlighting these sequencing platforms as contributors to instrument revenue and consumables usage. PacBio reports that its sequencing systems are supported by consumables, including sequencing chemistry and reagents, which contribute to its product revenue alongside instruments and services.

Business model and segment focus

PacBio operates through one reportable segment focused on the development, manufacturing, and marketing of an integrated platform for genetic analysis. Revenue is generated from product sales (instruments and consumables) and service and other revenue. PacBio derives a majority of revenue from the Americas, followed by the Asia-Pacific region and then Europe, the Middle East, and Africa.

PacBio’s press releases describe continued efforts to expand the use of its sequencing technologies in clinical research settings, including rare disease research, carrier screening, and other human health applications. However, the company consistently states that PacBio products are for research use only and not for use in diagnostic procedures.

Applications in human health and rare disease research

PacBio frequently highlights the role of its technologies in rare disease and clinical research. In a news release about a planned collaboration with the n-Lorem Foundation and EspeRare, PacBio describes how long-read whole-genome sequencing can support the development of individualized antisense oligonucleotide (ASO) therapies for ultra-rare genetic diseases. The company notes that ASO therapies require a complete understanding of genomic architecture, including variant phasing, structural variation, repeat expansions, and regulatory alterations that may be missed by standard sequencing approaches.

Under the proposed collaboration, PacBio plans to donate sequencing reagents and provide scientific expertise to support long-read genome analysis for research related to therapeutic treatments for individuals with rare diseases. The company positions long-read whole-genome sequencing as enabling infrastructure for scalable, genomics-driven therapy development in ultra-rare and nano-rare patient populations, while reiterating that its products are for research use.

HiFi sequencing in clinical research studies

PacBio’s news releases describe several large-scale research initiatives using its HiFi sequencing technology. For example, the company reports that a research effort led by UW Medicine and Seattle Children’s will employ PacBio HiFi whole-genome sequencing as a first-line approach to investigate Sudden Unexplained Death in Childhood (SUDC). In that project, trios from families are sequenced on PacBio’s Revio system using SPRQ-Nx chemistry, with the goal of increasing diagnostic yield by resolving complex variants, including structural variants and tandem repeats, and by incorporating parental data to understand inherited and de novo contributors to risk.

PacBio also highlights the HiFi Solves Consortium, a multi-center collaboration evaluating the clinical research utility of HiFi genomes. A study from the HiFi Solves EMEA Consortium, as described by PacBio, showed that HiFi sequencing combined with the Paraphase variant caller identified all known clinically relevant variants in a study cohort across complex genomic regions. PacBio presents this as evidence that high-accuracy long reads can bridge research and potential future clinical utility in genomics.

Technology innovation and methods development

Beyond its core platforms, PacBio participates in the development and dissemination of new sequencing methods that leverage its technologies. In collaboration with researchers at the University of California, Davis, PacBio announced CiFi, a community-developed long-read 3C method that combines chromatin conformation capture with HiFi sequencing. According to the company’s description, CiFi enables chromosome-scale, haplotype-resolved genome assemblies from a single sequencing run, particularly when sample material is limited.

PacBio reports that CiFi delivers multi-contact reads and longer fragments, increasing the information content of proximity ligation experiments. The method is presented as addressing limitations of short-read Hi-C by improving mapping in repetitive regions, enabling multi-contact resolution, and simplifying project workflows through use of a single sequencing platform.

Regulatory milestones and regional partnerships

PacBio also describes its role in supporting regulatory milestones for long-read sequencing. In partnership with Berry Genomics, the company announced that the Sequel II CNDx system received Class III Medical Device Registration approval from the National Medical Products Administration (NMPA) in China. PacBio characterizes this as the first regulatory clearance of a clinical-grade long-read sequencer, enabling clinicians in China to use PacBio HiFi sequencing for conditions such as thalassemia through Berry Genomics’ approved clinical assays and software.

PacBio explains that the Sequel II CNDx system leverages its Single Molecule, Real-Time (SMRT) technology, which the company describes as capable of delivering both high accuracy and long read lengths. In the context of thalassemia and other complex single-gene disorders, PacBio notes that HiFi sequencing can capture single nucleotide variants, insertions and deletions, copy number variants, structural variants, repeat expansions, and enable phasing in a single run.

Financial reporting and investor communications

PacBio provides regular financial updates through press releases and SEC filings. In its third quarter 2025 financial results and preliminary fourth quarter and full-year 2025 revenue announcements, the company reports revenue contributions from instruments, consumables, and service and other revenue. PacBio also discusses metrics such as system placements and consumable revenue, and it comments on initiatives like the introduction of SPRQ-Nx sequencing chemistry and expanded assay portfolios.

The company uses both GAAP and non-GAAP financial measures in its reporting, explaining that non-GAAP metrics are presented for supplemental informational purposes and are reconciled to GAAP measures. In an 8-K filing, PacBio notes that certain earnings-related press releases are furnished rather than filed for purposes of the Securities Exchange Act.

Position within the genomics research ecosystem

Across its news releases, PacBio presents itself as a premier life science technology company focused on sequencing solutions that address complex genomic questions. The company emphasizes collaborations with academic institutions, foundations, and commercial partners to extend the reach of HiFi long-read sequencing into areas such as rare disease research, biodiversity studies, functional genomics, and clinical research projects. PacBio also participates in investor conferences and industry events, where it discusses its technology, financial performance, and research collaborations.

While PacBio highlights the potential of its technologies to support precision medicine and clinical genomics, it consistently states that its products are provided for research use only and are not for use in diagnostic procedures. Investors and researchers considering PacBio stock (PACB) often evaluate the company based on its sequencing platforms, adoption of HiFi long-read sequencing in research and clinical research settings, and its ability to expand applications across human and non-human genomics.

Stock Performance

$1.93
-1.53%
-0.03
After hoursChange vs the $1.96 closeLast updated: November 13, 2026 at 18:42
+20.2%
Performance 1 year
$602.6M

Pacific Biosciences of California (PACB) closed at $1.96 on November 13, 2026. Over the past 12 months, the price has gained 20.2%.

See what a $1,000 investment in PACB would be worth today

Average down calculator for PACB

PACB Metrics & Rankings

Price returns through November 13, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
661,815
Shares Sold
1
Transactions
Most Recent Transaction
Gibson James R II (See Remarks) sold 661,815 shares @ $3.11 on October 6, 2026

Insider selling at Pacific Biosciences of California over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Pacific Biosciences of California generated $160.0M in revenue in FY2025, retaining a 28.6% gross margin, operating income reached -$553.9M, and net income was -$546.4M. Diluted earnings per share stood at -$1.82. The company generated -$111.2M in operating cash flow. The current ratio was 5.15, measuring current assets divided by current liabilities.

$160.0M
Revenue (FY2025)
-$546.4M
Net Income (FY2025)
-$111.2M
Operating Cash Flow

Upcoming Events

NOV
16
November 16, 2026 Marketing

Jefferies one-on-ones

Management to hold one-on-one investor meetings at Jefferies in London on Nov 16; schedule via investor relations (no webcast announced).
NOV
18
November 18, 2026 Marketing

Stephens fireside chat

Stephens NASH26 fireside chat in Nashville at 3:45 PM ET; will be webcast on the investor website with replays available for at least 30 days.

Pacific Biosciences of California has 2 upcoming scheduled events. The next event, "Jefferies one-on-ones", is scheduled for November 16, 2026 (today). Investors can track these dates to stay informed about potential catalysts that may affect the PACB stock price.

Short Interest History

Last 12 Months

Short interest in Pacific Biosciences of California (PACB) currently stands at 53.7 million shares, up 14.4% from the previous reporting period, representing 18.8% of the float. Since November 2025, short interest has increased by 57.7%.

Days to Cover History

Last 12 Months

Days to cover for Pacific Biosciences of California (PACB) currently stands at 4.1 days, up 89% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 34.4%. Across the settlements charted above, it has ranged from 2.2 to 10.5 days.

PACB Company Profile & Sector Positioning

Pacific Biosciences of California (PACB) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing PACB often look at related companies in the same sector, including Tactile Systems Technology, Inc. (TCMD), Sight Sciences, Inc. (SGHT), Cytek Biosciences, Inc. (CTKB), QuidelOrtho Corporation (QDEL), and Delcath Systems Inc (DCTH). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate PACB's relative position within its industry.

Frequently Asked Questions

The current stock price of Pacific Biosciences of California (PACB) is $1.93 in after-hours trading as of November 13, 2026.

The market cap of Pacific Biosciences of California (PACB) is approximately $602.6M. Learn more about what market capitalization means .

The FY2025 revenue of Pacific Biosciences of California (PACB) is $160.0M, from its most recent completed fiscal year.

The FY2025 net income of Pacific Biosciences of California (PACB) is -$546.4M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Pacific Biosciences of California (PACB) is -$1.82 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Pacific Biosciences of California (PACB) is -$111.2M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The gross profit margin of Pacific Biosciences of California (PACB) is 28.6% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Pacific Biosciences of California (PACB), current assets divided by current liabilities, was 5.15 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Pacific Biosciences of California (PACB) is $45.8M for FY2025, its most recent completed fiscal year.

The operating income of Pacific Biosciences of California (PACB) is -$553.9M for FY2025, its most recent completed fiscal year. Learn about operating income.

PacBio designs, develops, and manufactures advanced sequencing solutions for genetic analysis. The company focuses on high-quality, highly accurate sequencing technologies, including HiFi long-read sequencing, to help scientists and clinical researchers resolve genetically complex problems across a broad set of research applications.

PacBio operates in the analytical laboratory instrument manufacturing industry within the broader manufacturing sector. It develops, manufactures, and markets an integrated platform for genetic analysis and sequencing used in genomics research.

PacBio operates through one reportable segment focused on genetic analysis platforms. Revenue is generated from product sales, which include instruments and consumables, and from service and other revenue associated with its sequencing systems.

PacBio describes HiFi long-read sequencing as a high-accuracy long-read technology that can detect complex genomic variants and resolve challenging regions of the genome. It is used in whole-genome sequencing and other applications where comprehensive variant detection and detailed genomic architecture are important.

In its press releases, PacBio states that its products and technologies, including HiFi long-read sequencing, address applications such as human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging genomics research areas.

PacBio consistently states in its news releases that PacBio products are provided for research use only and are not for use in diagnostic procedures. While its technologies support clinical research and studies related to human health, they are not described as diagnostic products.

PacBio describes collaborations with organizations such as the n-Lorem Foundation and EspeRare to apply long-read whole-genome sequencing to ultra-rare and nano-rare genetic diseases. The company plans to donate sequencing reagents and scientific expertise to support research on individualized antisense oligonucleotide therapies and to improve understanding of complex genomic architecture in rare disease.

The HiFi Solves Consortium is described by PacBio as a group of clinical and research institutions evaluating the real-world utility of PacBio HiFi sequencing for human health applications. A study from the HiFi Solves EMEA Consortium reported that HiFi sequencing combined with the Paraphase variant caller identified all known clinically relevant variants in a cohort across complex genomic regions.

CiFi is a community-developed long-read 3C method announced by PacBio and UC Davis researchers. It combines chromatin conformation capture with PacBio HiFi sequencing to generate multi-contact reads and longer fragments, enabling chromosome-scale, haplotype-resolved genome assemblies from a single sequencing run, particularly when sample material is limited.

PacBio reports a long-standing partnership with Berry Genomics in China, through which the Sequel II CNDx system received Class III Medical Device Registration approval from the National Medical Products Administration. PacBio describes this as the first regulatory clearance of a clinical-grade long-read sequencer, enabling use of HiFi sequencing in clinical genomic testing workflows developed by Berry Genomics in China.

PacBio states in its press releases that it trades on NASDAQ under the ticker symbol PACB.

PacBio issues periodic press releases detailing its financial results, including revenue by category and key operating metrics, and files related information with the U.S. Securities and Exchange Commission. An 8-K filing dated November 5, 2025, notes that the company announced its third quarter 2025 financial results and furnished the related press release as an exhibit.